Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain

被引：16

作者：

Chivato T. ^{[1
]}

Álvarez-Calderón P. ^{[2
]}

Panizo C. ^{[3
]}

Abengozar R. ^{[4
]}

Alías C. ^{[5
]}

Al-Baech A. ^{[6
]}

Arias-Irigoyen J. ^{[6
]}

Caballero M.J. ^{[7
]}

Conill L. ^{[8
]}

Miguel S. ^{[9
]}

Laguna R. ^{[10
]}

Martínez-Benazet J. ^{[11
]}

Matoses F. ^{[12
]}

Martínez-Alonso J.C. ^{[13
]}

Mendizábal L. ^{[14
]}

Pérez-Carral C. ^{[15
]}

Puerto C. ^{[16
]}

Serra-Batllés J. ^{[17
]}

Vélez A. ^{[18
]}

Vicente J. ^{[19
]}

Torre F. ^{[20
]}

机构：

[1] Facultad de Medicina Universidad CEU San Pablo. Grupo Hospitales HM, Decanato. Facultad de Medicina, Avda. Montepríncipe s/n, Boadilla del Monte, Madrid

[2] Hospital Clínico Universitario de Santiago, La Coruña

[3] Hospital Ntra Sra del Prado, Toledo

[4] Hospital Virgen del Valle, Toledo

[5] Clínica Corachán, Barcelona

[6] Private Office, Huelva

[7] Clínica ASISA, Córdoba

[8] Hospital Can Misses, Ibiza

[9] Policlínico Salud 4, Madrid

[10] Private Office, Madrid

[11] Hospital Ntra Sra de Meritxell, Escaldes-Engordany

[12] Hospital General, Valencia

[13] Hospital Virgen de la Concha, Zamora

[14] Clínica Virgen de Fátima, Seville

[15] Hospital Comarcal da Costa, Lugo

[16] Private Office, Asturias

[17] Hospital de Vic, Barcelona

[18] Hospital San Juan de Dios, León

[19] Hospital General, Soria

[20] ALK-Abelló, S.A, Madrid

来源：

Clinical and Molecular Allergy | / 15卷 / 1期

关键词：

Allergen immunotherapy tablet; Allergic rhinitis; Clinical management; Expectations; Satisfaction;

D O I：

10.1186/s12948-016-0057-9

中图分类号：

学科分类号：

摘要：

Background: Sublingual immunotherapy has been proven as a well-tolerated and effective treatment for allergic rhinitis. Within this type of treatment, GRAZAX® is the most documented product in terms of safety and efficacy. The objective of this study was to identify the patients' expectations and level of treatment satisfaction, as well as the clinical management of patients with moderate/severe allergic rhinoconjunctivitis treated with GRAZAX®. Methods: This was a non-interventional, observational, multi-centre, open-label study involving a total of 131 adult patients aged 18-66 years with confirmed diagnosis of grass-allergy and initiated treatment with GRAZAX® between June 2010 and April 2011. Results: In the pollen season after starting treatment, 56.6% of patients stated that their symptoms were much less/less intense, 86% needed less symptomatic medication for control of their symptoms, and 74.4% manifested to have improved (quite/a lot) as regards their allergic disease since treatment was initiated as compared with previous grass pollen season. The patient satisfaction with GRAZAX® was measured using a visual analogue scale (VAS) between 0 (minimum satisfaction) and 100 (maximum satisfaction) comprising five different items: effectiveness, tolerability, cost, convenience and overall satisfaction. The results obtained for each item were [mean (SD)]: 74.7 (18.1), 70.3 (36.1), 39.3 (25.8), 86.2 (12.6), 78.4 (15.8) respectively. The patient's level of satisfaction is highly influenced, especially in terms of assessment of effectiveness, tolerability and convenience, by the information provided by the specialist. Conclusions: In summary, it can be concluded that improved communication leads to increased patient knowledge, greater patient compliance, and increased patient satisfaction. © 2017 The Author(s).

引用

共 27 条

[1]

Bauchau V., Durham S.R., Prevalence and rate of diagnosis of allergic rhinitis in Europe, Eur Respir J, 24, pp. 758-764, (2004)

[2]

Bousquet J., Cauwenberge P., Khaltaev N., Allergic rhinitis and its impact on asthma (ARIA), J Allergy Clin Immunol, 108, 5, pp. S147-334, (2001)

[3]

Radulovic S., Calderon M.A., Wilson D., Durham S., Sublingual immunotherapy for allergic rhinitis (Review) 2011, Cochrane Database Syst Rev, 12, (2010)

[4]

Malling H.J., Lund L., Ipsen H., Poulsen L., Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets, JIACI, 16, pp. 162-168, (2006)

[5]

Durham S., Yang W.H., Pedersen M.R., Johansen N., Rak S., Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis, JACI, 117, pp. 802-809, (2006)

[6]

Calderon M.A., Birk A.O., Andersen J.S., Durham S.R., Prolonged pre-seasonal treatment phase with SLIT increases clinical efficacy, Allergy, 62, pp. 958-961, (2007)

[7]

Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimming M., Klimek L., Knect R., Stephan V., Tholstrup B., WeiBhaar C., Kaiser F., Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy, J Allergy Clin Immunol, 123, pp. 167-173, (2009)

[8]

Kleine-Tebbe J., Ribel M., Herold D.A., Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial, Allergy, 61, pp. 181-184, (2006)

[9]

Dahl R., Kapp A., Colombo G., Monchy J.G.R., Rak S., Emminger W., Fernandez Rivas M., Ribel M., Durham S., Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis, JACI, 118, pp. 434-440, (2006)

[10]

Durham S., Emminger W., Kapp A., Colombo G., Monchy J.G.R., Rak S., Scadding G.K., Andersen J.S., Riis B., Long-term clinical efficacy in grass pollen rhinoconjunctivitis after treatment with SQ standardized grass allergy immunotherapy tablet, J Allergy Clin Immunol, 125, pp. 131-138, (2010)

← 1 2 3 →